Oncology
Redefining cancer treatment to one day eliminate cancer as a cause of death.
We strive to eliminate cancer as a cause of death
AstraZeneca has more than half a century of experience in cancer research and the development of effective cancer therapies. Our ambition is to give even more cancer patients hope for better treatment with the help of new active ingredients. That's why we focus on research and development to create a new generation of medicines that have the potential to redefine cancer treatment.
In Switzerland, we are currently conducting 14 international or national oncology trials in ovarian, breast-, bladder- and non-small cell lung cancer (as of 02/2020).
Key disease areas
Our scientific platforms
We’re concentrating on these scientific platforms that we believe show the greatest potential for yielding effective cancer medicines.
-
Immuno-Oncology Therapies
Activating the body’s own immune system to help fight cancer.
-
Tumour Drivers and Resistance
Targeting the genetic mutations and resistance mechanisms that enable cancer cells to evade treatment, survive, and proliferate.
-
DNA Damage Response
Targeting the DNA repair process to block cancer cells’ ability to reproduce.
-
Antibody Drug Conjugates (ADC)
Arming antibodies with cancer-killing agents for specific tumour targeting.
Our clinical study program
Gaining new insights into the diagnosis and therapy of numerous diseases.
Join AstraZeneca
and help us deliver life-changing medicines.
Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.
CH-2305; 03/2020